IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Journal Article (Journal Article;Systematic Review)

Chronic pruritus is a debilitating symptom with limited treatment options. Identifying molecular targets underlying chronic pruritic dermatoses is essential for the development of novel, targeted therapies. IL-31 is an important mediator of itch by integrating dermatologic, neural, and immune systems. IL-31 helps induce and maintain chronic pruritus via both indirect stimulation of inflammatory cells and through direct neural sensitization. IL-31 is overexpressed in various chronic pruritic skin conditions, and exogenous IL-31 induces itch and scratching behavior. Studies have demonstrated that IL-31R and IL-31 antagonism significantly reduces itch in patients with atopic dermatitis and prurigo nodularis, two extremely pruritic skin conditions. Emerging evidence, including recent phase II clinical trials of IL-31R antagonists, demonstrates that IL-31 plays an important role in itch signaling. Additional studies are ongoing to evaluate IL-31R and IL-31 antagonism as treatments of chronic pruritus.

Full Text

Duke Authors

Cited Authors

  • Roh, YS; Choi, J; Sutaria, N; Belzberg, M; Kwatra, MM; Kwatra, SG

Published Date

  • June 2021

Published In

Volume / Issue

  • 81 / 8

Start / End Page

  • 895 - 905

PubMed ID

  • 33881741

Electronic International Standard Serial Number (EISSN)

  • 1179-1950

Digital Object Identifier (DOI)

  • 10.1007/s40265-021-01521-1


  • eng

Conference Location

  • New Zealand